Last reviewed 2026-04-20 · How we verify

Pf-07999415 (pf-07999415)

PF-07999415 is a marketed drug by Pfizer Inc. It has a revenue of 63.6B. Unfortunately, no FDA-approved indications were found for this drug. The mechanism of action is not specified. Further information is needed to provide a clinical differentiation and commercial significance. No pipeline developments were found.

At a glance

Approved indications

• No FDA-approved indications found for PF-07999415
• Please note that this information might not be up-to-date or accurate

Common side effects

No common side effects on file.

Drug interactions

• Warfarin
• Aspirin
• Pentobarbital
• Clopidogrel
• Dabigatran
• Rivaroxaban
• Apixaban
• Esomeprazole
• Omeprazole
• Lansoprazole
• Pantoprazole
• Rabeprazole

Key clinical trials

• A Study to Learn How Different Amounts of the Study Medicine Called PF-07999415 Are Tolerated and Act in the Body in Healthy Adults (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Pf-07999415 CI brief — competitive landscape report
• Pf-07999415 updates RSS · CI watch RSS
• Pfizer portfolio CI